Erdosteine affects eicosanoid production in COPD

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 41-45

  Dal Negro, R W ^a   Visconti, M ^a   Tognella, S ^a   Micheletto, C ^a  

^a Orlandi General Hospital   (Italy)

Author keywords

COPD; Erdosteine; Leukotrienes; Oxidative stress; ROS

Indexed keywords

ERDOSTEINE; ICOSANOID; LEUKOTRIENE B4; LEUKOTRIENE E4; PLACEBO; REACTIVE OXYGEN METABOLITE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; FATTY ACID BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; ICOSANOID METABOLISM; LUNG FUNCTION TEST; MALE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE LEVEL;

AGED; ANTIOXIDANTS; DOUBLE-BLIND METHOD; EICOSANOIDS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE B4; LEUKOTRIENE E4; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES; THIOGLYCOLATES; THIOPHENES;

EID: 78650809919     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49041     Document Type: Article

References (25)

1. Rouzer CA, Samuelsson B. The importance of hydroperoxide activation for the detection and assay of mammalian 5-lipoxygenase. FEBS Lett. 1986; 204: 293-296. (Pubitemid 17177117)
2. Santus P, Sola A, Carlucci P, Fumagalli F, Di Gennaro A, Mondoni M et al. Lipid peroxidation and 5-lypoxygenase activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171: 838-843. (Pubitemid 40562714)
3. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor and leukotriene synthesis inhibitors in asthma: un update. Part 1: synthesis, receptors and role of leukotrienes in asthma. Pharmacol Res. 1999; 40: 3-13.
4. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax. 2003; 58: 585-588.
5. Barnes PJ. ABC of chronic obstructive pulmonary disease. Future treatments. BMJ. 2006; 333: 246-248.
6. Marchioni CF, Moretti M, Muratori M et al. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in obstructive pulmonary disease. Lung. 1990; 68: 285-293. (Pubitemid 20364628)
7. Olivieri D, Del Donno M, Casalini A, D'Ippolito R, Fregnan GB. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration. 1991; 58: 91-94.
8. Dal Negro RW, Visconti M, Micheletto C, Tognella S. Changes in blood ROS, e-NO and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: A controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008; 21: 304-308. (Pubitemid 351320569)
9. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Resp Med. 2007; 1: 307-316.
10. Dal Negro RW. Erdosteine: Anti-tussive and anti-inflammatory effects. Lung. 2008; 186 (Suppl): 70-73.
11. Dal Negro RW, Visconti M, Micheletto C et al. Valori di normalità e ripetibilità delle misure di stress ossidativo determinate mediante Fort System (in Italian with English Abstract). It J Chest Dis. 2003; 57: 199-209.
12. Braga PC, Dal Sasso M, Zuccotti T. Assessment of the antioxidant activity of the SH Metabolite I of erdosteine on human neutrophils respiratory burst. Arzneim-Forsch/Drug Res. 2000; 50: 739-746.
13. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res. 2006; 55: 249-254.
14. Dal Negro RW, Visconti M, Trevisan F, Bertacco S, Micheletto C, Tognella S. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Ther Adv Respir Dis. 2008; 2: 271-277.
15. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 1999; 160: 893-898. (Pubitemid 29442027)
16. Dahlen SE, Björk J, Hedqvist P, Arfors KE, Hammarström S, Lindgren JÅ, Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA. 1981; 78: 3887-3891.
17. Shimizu T, Shimizu S, Hattori R, Majima Y. A mechanism of antigen-induced goblet cell degranulation in the nasal epithelium of sensitized rats. J Allergy Clin Immunol. 2003; 112: 119-125. (Pubitemid 36819816)
18. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodelling. J Allergy Clin Immunol. 2003; 111: 18-34.
19. Clarke DL, Dakshinamurti S, Larsson AK, Ward JE, Yamasaki A. Lipid metabolites as regulators of airway smooth muscle function. Pulm Pharmacol Ther. 2009; 22: 426-435.
20. Pace E, Profita M, Melis M, Bonanno A, Paternò A, Mody CH et al. LTB4 is present in exudative pleural effusions and contribute actively to neutrophil recruitment in inflamed pleural space. Clin Exp Immunol. 2004; 135: 519-527. (Pubitemid 38297156)
21. Mehrotra AK, Henderson WR. The role of leukotrienes in airway remodeling. Curr Mol Med. 2009; 9: 383-391.
22. Fioretti M, Bandera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med Praxis. 1991; 12: 219-227.
23. Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: The Equalife study. Drugs Exptl Clin Res. 2004; 30: 143-152.
24. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin Drug Metab Toxicol. 2009; 5: 333-343.
25. Calverley PM. COPD: what is the unmet need? Br J Pharmacol. 2008; 155: 487-493.